While we deliberately excluded cases with ambiguity or TERT/ALT heterogeneity from the ALT-positive subgroup to enhance clarity regarding the impact of ALT on neuroblastoma patient prognosis, we included these cases in an independent small sub-cohort to determine the influence of both ALT and TERT positivity on patients’ survival. This evidence concerns the gene TERT and neuroblastoma.